Leerink Partners Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price

Amgen (NASDAQ:AMGN) had its price target boosted by Leerink Partners from $305.00 to $355.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an outperform rating on the medical research company’s stock.

Several other analysts have also recently issued reports on the stock. Scotiabank started coverage on shares of Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price on the stock. BMO Capital Markets raised their price objective on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Guggenheim lifted their target price on Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a report on Tuesday, January 20th. Finally, Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus target price of $347.65.

Amgen Stock Performance

NASDAQ AMGN opened at $366.22 on Wednesday. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. Amgen has a 1-year low of $261.43 and a 1-year high of $368.75. The business has a 50 day simple moving average of $333.19 and a two-hundred day simple moving average of $310.44. The stock has a market capitalization of $197.20 billion, a PE ratio of 25.74, a P/E/G ratio of 2.98 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 152.71% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the prior year, the company earned $5.31 EPS. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts predict that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio is 73.57%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares of the company’s stock, valued at $2,436,703.50. The trade was a 30.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.76% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Sequoia Financial Advisors LLC lifted its holdings in Amgen by 2.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after buying an additional 3,619 shares in the last quarter. Atlantic Union Bankshares Corp raised its stake in shares of Amgen by 165.0% in the second quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock valued at $2,972,000 after acquiring an additional 6,627 shares in the last quarter. Davis Capital Management purchased a new position in Amgen in the third quarter valued at $1,841,000. D.A. Davidson & CO. grew its stake in Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after purchasing an additional 6,222 shares in the last quarter. Finally, Global Wealth Management Investment Advisory Inc. increased its holdings in Amgen by 56.2% during the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after purchasing an additional 4,699 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat and company guidance lifted — Amgen reported Q4 EPS and revenue above Street estimates and issued FY‑2026 EPS and revenue guidance that came in around expectations while signaling continued product-volume growth; this is the primary catalyst pushing the stock higher. Amgen quarterly results beat Street estimates on higher sales, lower tax rate
• Positive Sentiment: Goldman Sachs raised its price target to $415 and kept a Buy rating — a high-profile upward revision that signals confidence in Amgen’s growth runway and likely supports further buying interest. Goldman Sachs adjusts price target on Amgen to $415 from $403, maintains Buy
• Positive Sentiment: Portfolio & pipeline momentum — coverage notes highlight double‑digit revenue and EPS growth for 2025 and faster uptake of new Amgen products (including obesity assets) that underpin the company’s guidance and longer‑term upside. Amgen posts double-digit revenue and EPS growth for 2025
• Positive Sentiment: Obesity program and late‑stage data in focus — investors are increasingly oriented toward MariTide/MariTide‑related obesity studies and other pipeline catalysts that could materially add revenue, helping explain enthusiastic flows. AMGN’s Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus
• Positive Sentiment: Technical/institutional signal — the stock is trading near 52‑week highs and commentary suggests heavy institutional buying, reinforcing momentum into today’s session. Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?
• Neutral Sentiment: Cantor Fitzgerald raised its price target to $350 but kept a Neutral rating — PT higher but rating unchanged, so limited directional push from this call. Amgen (AMGN) PT Raised to $350 at Cantor Fitzgerald
• Neutral Sentiment: Morgan Stanley nudged its target to $309 but kept an Equal‑Weight rating — the firm raised its view slightly but still implies downside vs. the current price, so the call is not uniformly bullish. Morgan Stanley raises price target on Amgen to $309 from $304, keeps Equal-Weight
• Negative Sentiment: Analysts flag execution/legacy‑product risks — some coverage (Citi and others) notes legacy product erosion and execution risks that could temper upside if new products don’t scale as expected. That is the key watch‑out for investors despite today’s positive headlines. Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.